FierceBiotech 13. Apr. 2026 Regeneron rides into radiopharma via $2.1B biobucks pact with Australia’s Telix
FierceBiotech 13. Apr. 2026 Allogene’s off-the-shelf CAR-T erases lingering lymphoma cells in early slice of data
FierceBiotech 12. Apr. 2026 GSK CEO's 'scientific courage' propels plans for medley of phase 3 trials for Hansoh-partnered ADC
FierceBiotech 10. Apr. 2026 'Can it actually deliver?': Why Big Pharma is making the leap to the quantum realm
FierceBiotech 10. Apr. 2026 Philips recalls Trilogy Evo ventilator software, warns of ‘under-delivery’ of therapy
FierceBiotech 9. Apr. 2026 J&J launches latest version of its pulsed ablation device after nabbing CE Mark
FierceBiotech 9. Apr. 2026 Judge rules that HHS must face states' lawsuit over RFK Jr.'s agency overhaul, massive layoffs
FierceBiotech 9. Apr. 2026 'It’s going to be huge': The 'diabolical' molecule poised to become biotech's next gold rush
FierceBiotech 9. Apr. 2026 Gilead pays Kymera $45M to glue preclinical protein degrader onto burgeoning oncology pipeline
FierceBiotech 9. Apr. 2026 Boehringer hands over funding, marketing rights for Click’s digital therapeutic
FierceBiotech 9. Apr. 2026 In a first, a CAR-T cell therapy drives 3 autoimmune diseases into remission in a single patient
FierceBiotech 9. Apr. 2026 Avalyn plans IPO to fund phase 3 trials of inhaled versions of approved respiratory drugs
FierceBiotech 9. Apr. 2026 Roche takes 'leap of faith' with $20M bet on C4T’s antibody-targeted protein degraders
FierceBiotech 8. Apr. 2026 Medline hit with FDA warning letter over defective heart syringes, safety hazards
FierceBiotech 8. Apr. 2026 Artivion nabs PMA clearance for aortic stent graft system, triggers Endospan buyout option